Monograph
G04CB01 - Finasteride |
Possibly porphyrinogenic |
PSP |
Rationale
Substrate for CYP 3A4. Conflicting evidence of porphyrinogenicity.
Chemical description
4-azasteroide used in prostatic hypertrophy, 5 mg/d Competetive inhibitor of 5-alpha reductase which converts testosterone to the more potent androgen dihydroform needed for the growth of the prostatic tissue. Metabolized by 3A4. South African list: use with extreme caution only. French list: authorized
IPNet drug reports
Uneventful use reported in 3 patients with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia
